drug

Old age is the main focus of a geriatrician, a doctor who is board certified in medicine and in geriatrics. Patients faced with old age and cancer have a lot to deal with, especially managing drug intake. Holly Holmes, M.D., Assistant Professor in the Department of General Internal Medicine and a certified geriatrician at the University of Texas MD Anderson Cancer Center, states her main focus is to help the senior cancer patient remain as functional and independent as possible. Being old in...

For more information about this resource, please see our blog post at URL http://blog.openhelix.eu/?p=9933. In this tip I introduce users to the VnD, or genetic Variation and Drug database from the Korean Bioinformation Center, or KOBIC.

MD Anderson's Dr. Michelle Fanale, Hodgkin lymphoma survivor Alexandra Medina and research nurse Rinata Simien talk about newly approved drug brentuximab vedotin.

Dana Vanderwall, Associate Director of Cheminformatics at Bristol-Myers Squibb, presented at Drexel University for Jean-Claude Bradley's Chemical Information Retrieval class on December 2, 2010. The first part covers "Cheminformatics & The evolving relationship between data in the public domain & pharma" and includes a general discussion of modern drug discovery and the details of a malaria dataset recently released from the pharmaceutical industry to the public. The second part describes...

Rajarshi Guha presents at the final fall 09 Chemical Information Retrieval class at Drexel University on December 3, 2009. The audio for the first 45 seconds is a little off but the rest is fine. Implicit and explicit molecular representations in 1D, 2D and 3D formats are introduced. Approaches to quantifying molecular similarity using fingerprinting are discussed, such as the Tanimoto index. The relevance of these methods to drug design in terms of virtual screening and QSAR is explored....

Mel Reichman, senior investigator and director of the LIMR Chemical Genomics Center at the Lankenau Institute for Medical Research presents at the chemistry department at Drexel University on November 12, 2009. Introduction by Jean-Claude Bradley. Modern drug discovery by high-throughput screening (HTS) begins with testing hundreds of thousands of compounds in biological assays. The confirmed hit rate for typical HTS is less than 0.5%; therefore, 99.5% of the costs of HTS are for...